Hereditary nonpolyposis colorectal cancer secondary prevention

Revision as of 16:21, 6 February 2019 by Ali Akram (talk | contribs)
Jump to navigation Jump to search

Hereditary Nonpolyposis Colorectal Cancer Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Hereditary Nonpolyposis Colorectal Cancer from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hereditary nonpolyposis colorectal cancer secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hereditary nonpolyposis colorectal cancer secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hereditary nonpolyposis colorectal cancer secondary prevention

CDC on Hereditary nonpolyposis colorectal cancer secondary prevention

Hereditary nonpolyposis colorectal cancer secondary prevention in the news

Blogs on Hereditary nonpolyposis colorectal cancer secondary prevention

Directions to Hospitals Treating Hereditary nonpolyposis colorectal cancer

Risk calculators and risk factors for Hereditary nonpolyposis colorectal cancer secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Maria Fernanda Villarreal, M.D. [2]

Overview

Secondary prevention strategies following hereditary nonpolyposis colorectal cancer include genetic testing, colonoscopy, urine cytology, pelvic exam and endometrial biopsy.

Secondary prevention

Recent studies demonstrate a reduced incidence in hereditary nonpolyposis colorectal cancer patients who were exposed to at least four years of high-dose aspirin, with a satisfactory risk profile. These results have been widely covered in the media; future studies will look at modifying (lowering) the dose (to reduce risk associated with the high dosage of ASA).

Secondary prevention strategies following hereditary nonpolyposis colorectal cancer include:[1]

  • Colonoscopy between 25-35 years, every 2 years.
  • Pelvic exam, transvaginal ultrasound and CA-125 between 25-35 years, every year.
  • Endometrial biopsy, in relation to clinical symptoms.
  • Urine cytology (families who have someone diagnosed with transitional cell carcinoma of the ureter or renal pelvis, between 25-35 years every year)

References

  1. Kladny J, Lubinski J. Lynch syndrome (HNPCC). Hered Cancer Clin Pract. 2008;6(2):99-102.


Template:WikiDoc Sources